Exploring the microRNA profiles as potential diagnostic probes for oligo- and polymetastatic prognosis of lung metastasis(es) patients

Wang, Zhichao; Gao, Shaolin; Li, Tiezhi; Ma, Xiaoyu; Zhu, Haiyong; Huang, Yan

doi:10.1097/md.0000000000010958

Cited by 5 publications

(3 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, recent data suggest that miRNA signatures might display tissue/organ specificity. Osaki et al reported that miR-143-3p expression decreased in a metastatic osteosarcoma cell line (143B) and primary osteosarcoma tissues with lung metastasis [85]. By comparing samples from patients without metastases and sample from those with lung metastases, Sasaki et al showed that increased expression of miR-27a and decreased miR-95-3p and miR-195 expression and miR-133 dysfunction are associated with which cancers develop lung metastasis [86].…”

Section: Genetic Signature Associated To Metastatic Tropism To Thementioning

confidence: 99%

Lung-Seeking Metastases

Stella

Kolling

Benvenuti

et al. 2019

Cancers

View full text Add to dashboard Cite

Metastases from different cancer types most often affect the lung parenchyma. Moreover, the lungs are among the most frequent sites of growth of metastatic masses of uncertain/unknown lineage of origin. Thus, with regards to pulmonary neoplastic parenchymal nodules, the critical issue is to determine if they are IN the lung or OF the lung. In this review, we highlight the clinical, instrumental and molecular features which characterize lung metastases, mainly focusing on recently advancing and emerging concepts regarding the metastatic niche, inflammation, angiogenesis, immune modulation and gene expression. A novel issue is related to the analysis of biomechanical forces which cooperate in the expansion of tumor masses in the lungs. We here aim to analyze the biological, genetic and pathological features of metastatic lesions to the lungs, here referred to as site of metastatic growth. This point should be a crucial part of the algorithm for a proper diagnostic and therapeutic approach in the era of personalized medicine.

show abstract

Section: Genetic Signature Associated To Metastatic Tropism To Thementioning

confidence: 99%

Lung-Seeking Metastases

Stella

Kolling

Benvenuti

et al. 2019

Cancers

View full text Add to dashboard Cite

show abstract

“…Several studies suggested that some genes and microRNA are expressed differently between two states, such as: PECAM1, KDR, PBK, and microRNA-200 family (miR-200b and miR-200c) and so on. [23][24][25][26] With the wide use of advanced imaging, researchers found that oligometastases not only existed in PCa, but also appeared in other cancers (includes bladder cancer, lung cancer, gastric cancer, esophagus cancer, etc.). [27][28][29][30] What's more, researchers found that T A B L E 5 Characteristics of studies included in the systematic review and meta-analysis | 741 surgical resection of the primary tumor may improve quality of patients' life and prolong their survival times who had various oligometastatic cancers.…”

Section: Discussionmentioning

confidence: 99%

Does surgery benefit patients with oligometastatic or metastatic prostate cancer? – A retrospective cohort study and meta‐analysis

Zheng

Wang

et al. 2021

The Prostate

View full text Add to dashboard Cite

show abstract

“…Oligometastases (OM) were defined as 1–5 lesions, while patients with 6+ lesions were designated as polymetastatic (PM) as previously described 2,24–26 . For any patients detected to have OM, detailed tumor burden data were collected at three timepoints: first visualization (earliest visualization, but not confirmation of suspicious lesions), confirmation (through biopsy or PET), and first treatment of metastases.…”

Section: Methodsmentioning

confidence: 99%

Oligometastatic adenoid cystic carcinoma: Correlating tumor burden and time to treatment with outcomes

et al. 2021

View full text Add to dashboard Cite

Background There is limited information on the management and outcomes of oligometastases (OM) in adenoid cystic carcinoma (ACC). Methods Retrospective study of 42 patients with metastatic ACC of the head and neck. Imaging studies were analyzed to identify patients with OM (1–5 lesions) at any point during follow‐up. Results There was radiographic evidence of OM in 33/42 (79%) patients. Eighteen patients had OM when treated for metastases, with median overall survival (OS) of 36.0 versus 9.2 years for patients with polymetastases (6+ lesions, HR 0.38, 95%CI 0.14–0.89). Earlier locally ablative treatment, but not systemic treatment, of patients with OM predicted improved survival 3 years after metastasis (HR 0.15, 95%CI 0.02–0.63) and postponed systemic treatment by 80 more months (HR 0.22, 95%CI 0.07–0.71). Conclusions There is a considerable population of ACC patients with detectable oligometastases, and early locally ablative treatment of oligometastases may be associated with improved outcomes.

show abstract

Exploring the microRNA profiles as potential diagnostic probes for oligo- and polymetastatic prognosis of lung metastasis(es) patients

Abstract: Supplemental Digital Content is available in the text

Cited by 5 publications

References 33 publications

Lung-Seeking Metastases

Lung-Seeking Metastases

Does surgery benefit patients with oligometastatic or metastatic prostate cancer? – A retrospective cohort study and meta‐analysis

Oligometastatic adenoid cystic carcinoma: Correlating tumor burden and time to treatment with outcomes

Contact Info

Product

Resources

About